Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study.

Int J Clin Pharm · 2026 · PMC12992448 · PMID 41201486

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally non-significantno p-value reported

The HR suggested a lower risk of severe and moderate exacerbations (0.80 [95% CI 0.69–0.93] and 0.80 [95% CI 0.74–0.87], respectively) and a marginally non-significant decreased risk of pneumonia (0.85 [95% CI 0.70–1.02]) associated with fluticasone/umeclidinium/vilanterol.

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.